Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern.

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

ENGLEWOOD, Colo. , March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").

Ampio Announces Voluntary Delisting and SEC Deregistration

ENGLEWOOD, Colo. , Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.

Ampio Provides Update on Results from Pre-IND Enabling Studies

ENGLEWOOD, Colo. , Jan. 11, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has reached settlements in principle in the pending securities fraud class action, Case Number 22-cv-2105-WJM-MEH (the "Securities Class Action"), and the pending consolidated derivative actions in the United States District Court for the District of Colorado, Case Number 22-cv-2803-KLM (the "Consolidated Derivative Actions").

Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions

ENGLEWOOD, Colo. , Oct. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that its CEO, Michael A.

Ampio Pharmaceuticals to Present at the Emerging Growth Conference

ENGLEWOOD, Colo. , Oct. 5, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has selected Ascendia Pharmaceuticals, Inc. ("Ascendia") to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain.

Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201

ENGLEWOOD, Colo. , Aug. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company's common stock.

Ampio Pharmaceuticals Announces Reverse Stock Split

BioMarin Pharmaceutical

Harmony Biosciences Holdings

The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.

3 Biotech Stocks to Buy With Explosive Upside Potential

ENGLEWOOD, Colo. , May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m.

Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock

ENGLEWOOD, Colo. , April 18, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.

AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS

Wilmington, Delaware--(Newsfile Corp. - February 7, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-ampio-pharmaceuticals-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ampio Pharmaceuticals, Inc.

ENGLEWOOD, Colo. , Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards.

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

ENGLEWOOD, Colo. , Nov. 17, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the "Company") received notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American.

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), announced today that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implement a fifteen-to-one reverse stock split.

Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split

NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ampio Pharmaceuticals, Inc.. Shareholders who purchased shares of AMPE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Ampio Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2022 - (NYSE: AMPE)

Los Angeles, California--(Newsfile Corp. - October 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (OTC Pink: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (OTC Pink: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"), of the important October 17, 2022 lead plaintiff deadline.

AMPE DEADLINE TODAY: ROSEN, A TOP RANKED FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPE

LOS ANGELES, CA / ACCESSWIRE / October 17, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (NYSE American:AMPE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 29, 2020 and August 3, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before October 17, 2022.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 16, 2022) - Levi & Korsinsky, LLP notifies investors in Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) of a class action securities lawsuit.The lawsuit on behalf of Ampio investors has been commenced in the the United States District Court for the District of Colorado.

Ampio Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 17, 2022 to Discuss Your Rights - AMPE

New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) ("Ampio" or the "Company"). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Ampio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ampio Pharmaceuticals, Inc. - AMPE

NEW YORK , Oct. 16, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (OTC: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"), of the important October 17, 2022  lead plaintiff deadline. SO WHAT: If you purchased Ampio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPE

Proposal to Authorize Reverse Stock Split has Been Approved ENGLEWOOD, Colo. , Oct. 14, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino.

Ampio Pharmaceuticals Issues Letter to Stockholders

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. (AMPE)

Los Angeles, California--(Newsfile Corp. - October 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (OTC Pink: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Ampio Pharmaceuticals, Inc. (NYSE: AMPE). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/ampio-pharmaceuticals-inc-loss-submission-form/?id=32598&from=4 This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020 and August 3, 2022, inclusive.

News for Ampio Pharmaceuticals Inc Stock (AMPE)